Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model.

Pubmed ID: 23788362

Journal: Statistics in medicine

Publication Date: Dec. 10, 2013

Affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, U.S.A.

MeSH Terms: Humans, Randomized Controlled Trials as Topic, Heart Failure, Confidence Intervals, Computer Simulation, Models, Statistical, Ventricular Dysfunction, Left, Enalapril

Authors: Kovalchik SA, Varadhan R, Weiss CO

Cite As: Kovalchik SA, Varadhan R, Weiss CO. Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model. Stat Med 2013 Dec 10;32(28):4906-23. Epub 2013 Jun 21.

Studies:

Abstract

Understanding how individuals vary in their response to treatment is an important task of clinical research. For standard regression models, a proportional interactions model first described by Follmann and Proschan (1999) offers a powerful approach for identifying effect modification in a randomized clinical trial when multiple variables influence treatment response. In this paper, we present a framework for using the proportional interactions model in the context of a parallel-arm clinical trial with multiple prespecified candidate effect modifiers. To protect against model misspecification, we propose a selection strategy that considers all possible proportional interactions models. We develop a modified Bonferroni correction for multiple testing that accounts for the positive correlation among candidate models. We describe methods for constructing a confidence interval for the proportionality parameter. In simulation studies, we show that our modified Bonferroni adjustment controls familywise error and has greater power to detect proportional interactions compared with multiplcity-corrected subgroup analyses. We demonstrate our methodology by using the Studies of Left Ventricular Dysfunction Treatment trial, a placebo-controlled randomized clinical trial of the efficacy of enalapril to reduce the risk of death or hospitalization in chronic heart failure patients. An R package called anoint is available for implementing the proportional interactions methodology.